The most-recognized respiratory brand in North America is Advair. The brand was most recognized by 13.7 percent of physicians in a survey conducted by Brand Institute Inc. in first-quarter 2013. Advair, comprising fluticasone propionate and salmeterol xinafoate, is marketed by GlaxoSmithKline (gsk.com). Since its initial approval by FDA in 2000, Advair’s various formulations have earned indications for long-term, twice-daily, maintenance treatment of asthma in patients 12 years old or older and for the maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
Spiriva is the second most-recognized respiratory brand in North America. About 7 percent of physicians recognize this brand the most. Spiriva, comprising tiotropium, is marketed by Boehringer Ingelheim (boehringer-ingelheim.com) and Pfizer Inc. (pfizer.com). The product was first approved by FDA in January 2004 for the long-term once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, and for reducing COPD exacerbations.
The third most-recognized respiratory brand in North America is Ventolin. About 5 percent of physicians recognize this brand the most. Ventolin is GlaxoSmithKline’s brand name for albuterol, which was first marketed by Allen and Hanburys (now part of GlaxoSmithKline) in 1968 and is sold by several companies under a number of brand names for the relief of bronchospasm in asthma and chronic obstructive pulmonary disease.
The most-recognized respiratory brand in Europe is Ventolin. About 13.5 percent of physicians recognize this brand the most.
Spiriva is the second most-recognized respiratory brand in Europe. About 5.6 percent of physicians recognize this brand the most.
The third most-recognized pain and inflammation brand in Europe is Atrovent. About 3.8 percent of physicians recognize this brand the most. Atrovent, comprising ipratropium, is marketed by Boehringer Ingelheim. The product in its various formulations is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema; and for symptomatic relief of rhinorrhea associated with the common cold and allergic and nonallergic rhinitis.
Brand Institute (brandinstitute.com) surveyed more than 2,000 physicians and hospital and retail pharmacists in North America and Europe to determine the most-recognizable brands in the category of respiratory. Brandpoll is the company’s marketing tool and is designed to help clients monitor the competitive marketplace and identify the potential strengths and weaknesses of their brands.
Posted: October 2013
View comments